Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

115 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P, Alm GV, Fredrikson S, Link H. Kivisäkk P, et al. Among authors: alm gv. Eur J Neurol. 2000 Jan;7(1):27-34. doi: 10.1046/j.1468-1331.2000.00002.x. Eur J Neurol. 2000. PMID: 10809912 Clinical Trial.
Monoclonal antibody two-site ELISA for human IFN-gamma. Adaptation for determinations in human serum or plasma.
Andersson G, Ekre HP, Alm G, Perlmann P. Andersson G, et al. J Immunol Methods. 1989 Dec 20;125(1-2):89-96. doi: 10.1016/0022-1759(89)90081-1. J Immunol Methods. 1989. PMID: 2514232
Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P, Alm GV, Tian WZ, Matusevicius D, Fredrikson S, Link H. Kivisäkk P, et al. Among authors: alm gv. Mult Scler. 1997 Jun;3(3):184-90. doi: 10.1177/135245859700300303. Mult Scler. 1997. PMID: 9310964
Induction of mRNA for HLA-DR beta in human keratinocytes cocultured with interferon-gamma.
Nilsson H, Johansson C, Sandberg K, Funa K, Alm GV, Scheynius A. Nilsson H, et al. Among authors: alm gv. Arch Dermatol Res. 1989;281(4):260-6. doi: 10.1007/BF00431060. Arch Dermatol Res. 1989. PMID: 2476082
Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K, Alm GV. Oberg K, et al. Among authors: alm gv. J Interferon Res. 1989 Sep;9 Suppl 1:S45-9. J Interferon Res. 1989. PMID: 2809277
Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment.
Rönnblom LE, Janson ET, Perers A, Oberg KE, Alm GV. Rönnblom LE, et al. Among authors: alm gv. Clin Exp Immunol. 1992 Sep;89(3):330-5. doi: 10.1111/j.1365-2249.1992.tb06957.x. Clin Exp Immunol. 1992. PMID: 1516252 Free PMC article.
Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K, Alm G, Magnusson A, Lundqvist G, Theodorsson E, Wide L, Wilander E. Oberg K, et al. J Natl Cancer Inst. 1989 Apr 5;81(7):531-5. doi: 10.1093/jnci/81.7.531. J Natl Cancer Inst. 1989. PMID: 2466128
The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors.
Oberg K, Alm G. Oberg K, et al. Biotherapy. 1997;10(1):1-5. doi: 10.1007/BF02678211. Biotherapy. 1997. PMID: 9261544 Review.
Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response.
Imam H, Janson ET, Gobl A, Alm G, Oberg K. Imam H, et al. Anticancer Res. 1995 Sep-Oct;15(5B):2191-5. Anticancer Res. 1995. PMID: 8572623
Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon.
Oberg K, Norheim I, Alm G. Oberg K, et al. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1475-9. doi: 10.1016/0277-5379(89)90107-7. Eur J Cancer Clin Oncol. 1989. PMID: 2480243 Clinical Trial.
115 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback